Awaiting a potential acquisition by Novo Holdings, Catalent is giving its contract manufacturing compatriot a boost as Ardena plots its U.S. debut. Catalent is selling its oral solids development ...

The firms entered into a merger agreement in February for Novo Holdings to acquire Catalent in an all-cash transaction worth $16.5 billion. That deal still expects to close toward the end of ...

Catalent (NYSE:CTLT) is selling its oral solids development and small-scale manufacturing facility in Somerset, New Jersey to contract manufacturer Ardena. Financial details of the agreement ...

A Catalent spokesperson reiterated the company's position on the deal in a statement on Friday to Reuters in response to the letter: "Novo Holdings’ pending acquisition of Catalent will further ...

SOMERSET, N.J. - Catalent, Inc. (NYSE: NYSE:CTLT), a global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, has reached a ...

(RTTNews) - Catalent, Inc. (CTLT), a provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, Monday said it has agreed to sell its ...

Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, announced today that it has entered into a definitive agreement to sell ...

The transaction – first announced in February – would see Novo Nordisk's parent company Novo Holdings buy contract development and manufacturing organisation (CDMO) Catalent outright for $16.5 ...

Pace Life Sciences, a division of the broader Pace organization, has acquired a laboratory in Morrisville from Catalent (NYSE: CTLT) that focuses on analytical services. Catalent is a contract ...

U.S. Sen. Elizabeth Warren has asked the Federal Trade Commission “closely scrutinize” a $16.5 billion deal in which Novo Nordisk’s parent foundation would acquire Catalent, a leading ...

Novo Holdings, the investment firm that has a controlling interest in Novo Nordisk, signed a $16.5 billion deal to buy Catalent in February to boost supply of Wegovy, Novo's blockbuster GLP-1 ...

Robert W. Baird analyst Eric Coldwell downgraded the rating on Catalent (CTLT – Research Report) to a Hold today, setting a price target of $63.50. Eric Coldwell has given his Hold rating due to ...